MedX Holdings, Inc. is a publicly trading holding company utilizing a new form of Collaborative Governance. MEDH targets the acquisitions of undervalued, turnaround medical related businesses. In addition, MedX Pharmaceuticals a wholly-owned subsidiary of MEDH is newly emerging as dynamic distributor of an array pharmaceutical products.For more information about MedX Holdings, Inc., call (877) 225-0243 or visit our web site www.medxholdings.com is located at 1621 Central Avenue, Cheyenne, WY, USA Safe-Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the company's Forms 10-K and 10-Q filed with the SEC.
CHEYENNE, Wyo., July 12, 2016 (GLOBE NEWSWIRE) -- MedX Holdings, Inc. (OTC PINK:MEDH) in keeping with our promise to be completely transparent with our investors we want to discuss why MEDH is currently a non-reporting public company. We chose to acquire a public company on the OTC Pinks (non-reporting). This was designed to allow the time to build a foundation while creating assets and revenue without the undue burden of a 2-Year audit and up to $200,000 in accounting fees in the first fiscal year. As a result, when MEDH reaches 25M to 75M in combined Assets and Revenue we will elect to Audit the entire company and up list to an Exchange or OTC QB which, we may reach in 2016! MEDH is also in the final stages of making an offer on a sales office in Fort Lauderdale, Florida which will be the main sales center for our pharmaceutical sales team. To lead the charge, Charles Munro has agreed to accept the position of Director of Sales for MedX Pharmaceuticals. Mr. Munro joins MedX Pharmaceuticals, Inc. with 20 years of progressively responsible experience directing sales and marketing employees. He has worked in publicly traded companies overseeing staff of upwards to 100+ employees with revenues in excess of $2B annually. Mr. Munro has led various companies through start-up, survival, turnaround and growth modes. He brings a wealth of experience in understanding how to penetrate new markets and building on existing ones in the pharmaceutical sector. Mr. Munro received a BS in Consumer Studies with a minor of Entrepreneurship and Emerging Enterprises at Syracuse University. Ms. Roberton, CEO commented: "As our team expands so will our sales. Now that we are fully licensed as a Manufacture/Wholesaler/Repackager of pharmaceuticals our sales team can begin the sales phase which means substantial revenue for the first time in years!"